Earnings Call · Q4 FY2024·2025-02-25

Q4 24EPS +13.58%·Rev n/aQ3 24EPS +20.18%·Rev n/aQ2 24EPS +10.88%·Rev n/aQ1 24EPS -35.89%·Rev n/a⚠ consensus missing

Jazz Pharmaceuticals plc JAZZ

Jeff Macdonald — Investor Relations or Communications Officer

Bruce Cozadd — Chairman and Chief Executive Officer

Renée Galá — Head of Commercial or Commercial Executive

Robert Iannone — Chief Medical Officer or Head of R&D

Philip Johnson — Chief Financial Officer

+3.2%1d on move date+3.2% vs SPY3d+2.8%5d−0.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more JAZZ calls or request research access.

More JAZZ calls Browse calls Request research access